New UK Pathway Use Has ‘Far Exceeded Expectations’

Early/Mid-Development Stage Drugs Accounted For Most 1st-Year Requests

Oncology products accounted for the largest proportion of requests for a UK “innovation passport” last year, with a wide variety of drug sponsors deciding to use the new ILAP, according to the UK regulator, the MHRA.

Innovation letters — ILAP spells a new era in getting innovative medicines to patients • Source: Alamy

The number of applications to use the UK’s Innovative Licensing and Access Pathway (ILAP) far exceeded expectations in its first year of operation. That's according to Daniel O’Connor of the UK regulator, the MHRA, which operates the new scheme.

A total of 76 requests for an “innovation passport” were received last year following the launch of ILAP on at...